We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights
GCVRZ

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

Back to rankings

106 hedge funds and large institutions have $76.1M invested in Sanofi Contingent Value Rights in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 8

19% more capital invested

Capital invested by funds: $64M → $76.1M (+$12.1M)

6% more funds holding

Funds holding: 100 → 106 (+6)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

31% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 16

Holders
106
Holders Change
+6
Holders Change %
+6%
% of All Funds
2.43%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
11
Reduced
16
Closed
8
Calls
$724K
Puts
–
Net Calls
+$724K
Net Calls Change
+$112K

Top Buyers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
+$304K
2
SAM
Silverback Asset Management
North Carolina
+$157K
3
BRF
B. Riley Financial
California
+$114K
4
CI
Cowen Inc
New York
+$17.7K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$13.5K

Top Sellers

Rank Fund Capital Flow
1
CL
CSS LLC
Illinois
-$71.2K
2
PC
Pomelo Capital
New York
-$66.8K
3
PC
Permanens Capital
New York
-$48K
4
TL
TowerView LLC
New York
-$46.6K
5
DBG
De Burlo Group
Massachusetts
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
JGC
26
J. Goldman & Co
New York
$101K – – –
Wells Fargo
27
Wells Fargo
California
$79K -$193 -414 -0.3%
YCM
28
Yakira Capital Management
Connecticut
$78K – – –
AL
29
Arnhold LLC
New York
$73K – – –
UBS Group
30
UBS Group
Switzerland
$31K -$7.49K -16,082 -20%
GI
31
GAMCO Investors
Connecticut
$31K -$93 -200 -0.3%
Korea Investment Corp
32
Korea Investment Corp
South Korea
$25K – – –
Royal London Asset Management
33
Royal London Asset Management
United Kingdom
$22K +$20.5K +44,077 New
ZIG
34
Zuckerman Investment Group
Illinois
$21K -$70 -150 -0.4%
Morgan Stanley
35
Morgan Stanley
New York
$17K -$210 -451 -1%
CHAM
36
Clear Harbor Asset Management
Connecticut
$17K – – –
Ameriprise
37
Ameriprise
Minnesota
$17K +$14 +30 +0.1%
SDWMA
38
Schneider Downs Wealth Management Advisors
Pennsylvania
$13K – – –
Commonwealth Equity Services
39
Commonwealth Equity Services
Massachusetts
$12K -$180 -386 -2%
CS
40
Credit Suisse
Switzerland
$9K – – –
TSS
41
Two Sigma Securities
New York
$8K -$5.28K -11,323 -42%
Bank of America
42
Bank of America
North Carolina
$8K -$246 -529 -3%
HK
43
Horizon Kinetics
New York
$8K – – –
MC
44
Moors & Cabot
Massachusetts
$8K – – –
WEC
45
Winslow Evans & Crocker
Massachusetts
$8K +$653 +1,402 +100%
RWP
46
RWA Wealth Partners
Massachusetts
$8K +$6.99K +15,000 New
BIA
47
Biondo Investment Advisors
Pennsylvania
$7K – – –
FHA
48
Flagship Harbor Advisors
Massachusetts
$7K – – –
William Blair & Company
49
William Blair & Company
Illinois
$7K +$6.53K +14,005 +2,138%
BlackRock
50
BlackRock
New York
$6K – – –
1
2
3 4

GCVRZ Hedge Fund Activity: Q2 2018 in Review

106 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q2 2018, worth a combined $76.1M — up 19% from $64M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new GCVRZ positions and 8 closed out — a net gain of 7 holders — while 11 added to existing stakes and 16 trimmed.

The largest buyer was Highbridge Capital Management, adding an estimated $304K. The largest seller was CSS LLC, cutting an estimated $71.2K.

  • 106 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q2 2018, up from 100 in Q1 2018.
  • Funds reported $76.1M of Sanofi Contingent Value Rights stock for Q2 2018, up 19% quarter-over-quarter.
  • 15 funds opened new Sanofi Contingent Value Rights positions in Q2 2018 and 8 closed out, a net change of +7 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q2 2018 was Highbridge Capital Management, an estimated $304K added.
  • The largest Sanofi Contingent Value Rights seller in Q2 2018 was CSS LLC, an estimated $71.2K sold.

Based on aggregated 13F filings for Q2 2018.